Toxicity of polymeric nanoparticles in vivo and in vitro
Source abstract
Abstract
Polybutylcyanoacrylate nanoparticles (PBCA NPs) are candidates for a drug delivery system, which can cross the blood-brain barrier (BBB). Because little is known about their toxicity, we exposed cells to PBCA NPs in vitro and in vivo and monitored their life and death assays. PBCA NPs were fabricated with different surfactants according to the mini-emulsion technique. Viabilities of HeLa and HEK293 cells after NP incubation were quantified by analysing cellular metabolic activity (MTT-test). We then repetitively injected i.v. rhodamine-labelled PBCA NP variations into rats and monitored the survival and morphology of retrogradely labelled neurons by in vivo confocal neuroimaging (ICON) for five weeks. To test for carrier-efficacy and safety, PBCA NPs loaded with Kyotorphin were injected in rats, and a hot plate test was used to quantify analgesic effects. In vitro, we found dose-dependent cell death which was, however, only detectable at very high doses and mainly seen in the cultures incubated with NPs fabricated with the tensids SDS and Tween. However, the in vivo experiments did not show any NP-induced neuronal death, even with particles which were toxic at high dose in vitro, i.e. NPs with Tween and SDS. The increased pain threshold at the hot plate test demonstrated that PBCA NPs are able to cross the BBB and thus comprise a useful tool for drug delivery into the central nervous system (CNS). Our findings showing that different nanoparticle formulations are non-toxic have important implications for the value of NP engineering approaches in medicine.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Nanoparticle-Based Drug Delivery · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (33)
Show source-provided references
1. Ai J, Biazar E, Jafarpour M, Montazeri M, Majdi A, Aminifard S, Zafari M, Akbari HR, Rad HG (2011) Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomed 6:1117–1127
2. Alyautdin RN, Gothier D, Petrov VE, Kharkevich DA, Kreuter J (1995) Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 41:44–48
3. Couvreur P, Kante B, Grislain L, Roland M, Speiser P (1982) Toxicity of polyalkylcyanoacrylate nanoparticles. I. Doxorubicin-loaded nanoparticles. J Pharm Sci 71:790–79210.1002/jps.2600710717 ↗
4. De Jong WH, Borm PJ (2008) Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 3:133–14910.2147/IJN.S596 ↗
5. Dhawan A, Sharma V (2010) Toxicity assessment of nanomaterials: methods and challenges. Anal Bioanal Chem 398:589–60510.1007/s00216-010-3996-x ↗
6. Elsaesser A, Howard CV (2012) Toxicology of nanoparticles. Adv Drug Deliv Rev 64:129–13710.1016/j.addr.2011.09.001 ↗
7. Fröhlich E (2012) The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 7:5577–559110.2147/IJN.S36111 ↗
8. Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases. Neurobiol Disease 37:48–5710.1016/j.nbd.2009.07.028 ↗
9. Henrich-Noack P, Prilloff S, Voigt N, Jin J, Hintz W, Tomas J, Sabel BA (2012) In vivo visualisation of nanoparticle entry into the central nervous system tissue. Arch Toxicol 86:1099–110510.1007/s00204-012-0832-4 ↗
10. Henrich-Noack P, Voigt N, Prilloff P, Fedorov A, Sabel BA (2013) Transcorneal electrical stimulation alters morphology and survival of retinal ganglion cell after axonal damage. Neurosci Lett 543:1–610.1016/j.neulet.2013.03.013 ↗
11. Hussain SM, Hess KL, Gearhart JM, Geiss KT, Schlager JJ (2005) In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro 19:975–98310.1016/j.tiv.2005.06.034 ↗
12. Kante B, Couvreur P, Dubois-Krack G, De Meester C, Guiot P, Roland M, Mercier M, Speiser P (1982) Toxicity of polyalkylcyanoacrylate nanoparticles. J Pharm Sci 71:786–79010.1002/jps.2600710716 ↗
13. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA (1995) Passage of peptides through the blood–brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674:171–17410.1016/0006-8993(95)00023-J ↗
14. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN (1997) Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Control Release 49:81–8710.1016/S0168-3659(97)00061-8 ↗
15. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R (2002) Apolipoprotein mediated transport of nanoparticle-bound drugs across the blood–brain barrier. J Drug Target 10:317–32510.1080/10611860290031877 ↗
16. Ku S, Yan F, Wang Y, Sun Y, Yang N, Ye L (2010) The blood–brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biochem Biophys Res Commun 394:871–87610.1016/j.bbrc.2010.03.006 ↗
17. Lam CW, James JT, McCluskey R, Hunter RL (2004) Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci 77:126–13410.1093/toxsci/kfg243 ↗
18. Love SA, Maurer-Jones MA, Thompson JW, Lin YS, Haynes CL (2012) Assessing nanoparticle toxicity. Annu Rev Anal Chem 5:181–20510.1146/annurev-anchem-062011-143134 ↗
19. Nunes A, Al-Jamal KT, Kostarelos K (2012) Therapeutics, imaging and toxicity of nanomaterials in the central nervous system. J. Control Release 161:290–30610.1016/j.jconrel.2012.03.026 ↗
20. Nyström AN, Fadeel B (2012) Safety assessment of nanomaterials: implications for nanomedicine. J. Control Release 161:403–40810.1016/j.jconrel.2012.01.027 ↗
21. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, Cox C (2004) Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 16:437–44510.1080/08958370490439597 ↗
22. Prilloff S, Fan J, Henrich-Noack P, Sabel BA (2010) In vivo confocal neuroimaging (ICON): non-invasive, functional imaging of the mammalian CNS with cellular resolution. Eur J Neurosci 31:521–52810.1111/j.1460-9568.2010.07078.x ↗
23. Sabel BA, Engelmann R, Humphrey MM (1997) In vivo confocal neuroimaging of CNS neurons (ICON). Nat Med 3:244–24710.1038/nm0297-244 ↗
24. Sautter J, Sabel BA (1993) Recovery of Brightness discrimination in adult rats despite progressive loss of retrogradely labelled retinal ganglion cells after controlled optic nerve crush. Eur J Neurosci 5:680–69010.1111/j.1460-9568.1993.tb00533.x ↗
25. Sautter J, Schwartz M, Duvdevani R, Sabel BA (1991) GM1 ganglioside treatment reduces visual deficits after graded crush of the rat optic nerve. Brain Res 565:23–3310.1016/0006-8993(91)91732-G ↗
26. Schroeder U, Sabel BA (1996) Nanoparticles, a drug carrier system to pass the blood–brain barrier, permit central analgetic effects of i.v. dalargin injections. Brain Res 710:121–12410.1016/0006-8993(95)01375-X ↗
27. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA (1998) Nanoparticle technology for delivery of drugs across the blood–brain-barrier. Eur J Pharm Sci 87:1305–130710.1021/js980084y ↗
28. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR): Modified Opinion (after public consultation) (2006) on the appropriateness of existing methodologies to assess the potential risk associated with engineered as adventitious products of nanotechnologies. European Commission Health and Consumer Protection Directorate—General, Directorate C—Public Health and Risk Management, C7—Risk assessment, 10th Plenary Meeting, 10th of March 2006
29. Sharma A, Madhunapantula SV, Robertson GP (2012) Toxicological considerations when creating nanoparticle based drugs and drug delivery systems? Expert Opin Drug Metab Toxicol 8:47–6910.1517/17425255.2012.637916 ↗
30. Steuer H, Jaworski A, Stoll D, Schlosshauer B (2004) In vitro model of the outer blood-retina barrier. Brain Res Protoc 13:26–3610.1016/j.brainresprot.2003.12.002 ↗
31. Steuer H, Jaworski A, Elger B, Kaussmann M, Keldenich J, Schneider H, Stoll D, Schlosshauer B (2005) Functional characterization and comparison of the outer blood–retina barrier and the blood–brain barrier. Invest Ophthalmol Vis Sci 46:1047–105310.1167/iovs.04-0925 ↗
32. Weiss CK, Ziener U, Landfester K (2007) A route to nonfunctionalized and functionalized poly-(n-butylcyanoacrylate) nanoparticles: preparation in miniemulsion. Macromolecules 40:928–93810.1021/ma061865l ↗
33. Zhao J, Castranova V (2011) Toxicology of nanomaterials used in nanomedicine. J Toxicol Environ Health Part B 14:593–63210.1080/10937404.2011.615113 ↗